                         SEQUENCE LISTING

<110>  Snake River Bioscience, Inc.
 
<120>  Compositions and Methods for the Treatment of Major Depressive 
       Disorder

<130>  SNRB0001WO

<150>  62848816
<151>  2019-05-16

<160>  30    

<170>  PatentIn version 3.5

<210>  1
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-ceramide antibody heavy chain variable region CDR1

<400>  1

Gly Tyr Thr Phe Thr Asp His Thr Ile His 
1               5                   10  


<210>  2
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-ceramide antibody heavy chain variable region CDR2

<400>  2

Tyr Asn Tyr Pro Arg Asp Gly Ser Thr Lys Tyr Asn Glu Lys Phe Lys 
1               5                   10                  15      


Gly 
    


<210>  3
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-ceramide antibody heavy chain variable region CDR3

<400>  3

Gly Phe Ile Thr Thr Val Val Pro Ser Ala Tyr 
1               5                   10      


<210>  4
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-ceramide antibody light chain variable region CDR1

<400>  4

Arg Ala Ser Lys Ser Ile Ser Lys Tyr Leu Ala 
1               5                   10      


<210>  5
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-ceramide antibody light chain variable region CDR2

<400>  5

Ser Gly Ser Thr Leu Gln Ser 
1               5           


<210>  6
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-ceramide antibody light chain variable region CDR3

<400>  6

Gln Gln His Asn Glu Tyr Pro Trp Thr 
1               5                   


<210>  7
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-ceramide antibody heavy chain variable region CDR1

<400>  7

Gly Tyr Ala Phe Ser Ser Tyr Trp Met Asn 
1               5                   10  


<210>  8
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-ceramide antibody heavy chain variable region CDR2

<400>  8

Gln Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe Lys 
1               5                   10                  15      


Gly 
    


<210>  9
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-ceramide antibody heavy chain variable region CDR3

<400>  9

Arg Cys Tyr Tyr Gly Leu Tyr Phe Asp Val 
1               5                   10  


<210>  10
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-ceramide antibody light chain variable region CDR1

<400>  10

Lys Ala Ser Gln Asp Ile Asn Arg Tyr Leu Ser 
1               5                   10      


<210>  11
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-ceramide antibody light chain variable region CDR2

<400>  11

Arg Ala Asn Arg Leu Val Asp 
1               5           


<210>  12
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-ceramide antibody light chain variable region CDR3

<400>  12

Leu Gln Tyr Asp Glu Phe Pro Tyr Thr 
1               5                   


<210>  13
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-ceramide antibody heavy chain variable region CDR1

<400>  13

Gly Tyr Thr Phe Thr Ser Tyr Trp Met His 
1               5                   10  


<210>  14
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-ceramide antibody heavy chain variable region CDR2

<400>  14

Tyr Ile Asn Pro Ser Ser Gly Tyr Thr Lys Tyr Asn Gln Phe Lys Asp 
1               5                   10                  15      


<210>  15
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-ceramide antibody heavy chain variable region CDR3

<400>  15

Gly Gly Tyr Tyr Gly Phe Ala Tyr 
1               5               


<210>  16
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-ceramide antibody light chain variable region CDR1

<400>  16

Ser Ala Ser Ser Ser Val Ser Tyr Met Tyr 
1               5                   10  


<210>  17
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-ceramide antibody light chain variable region CDR2

<400>  17

Leu Thr Ser Asn Leu Ala Ser 
1               5           


<210>  18
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-ceramide antibody light chain variable region CDR3

<400>  18

Gln Gln Trp Ser Ser Asn Pro Leu Thr 
1               5                   


<210>  19
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-ceramide antibody heavy chain variable region CDR1

<400>  19

Gly Phe Ser Leu Thr Gly Tyr Gly Val His 
1               5                   10  


<210>  20
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-ceramide antibody heavy chain variable region CDR2

<400>  20

Val Ile Trp Ser Gly Gly Ser Thr Asp Tyr Asn Ala Ala Phe Ile Ser 
1               5                   10                  15      


<210>  21
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-ceramide antibody heavy chain variable region CDR3

<400>  21

Asn Tyr Gly Tyr Asp Tyr Ala Met Asp Tyr 
1               5                   10  


<210>  22
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-ceramide antibody light chain variable region CDR1

<400>  22

Arg Ala Ser Gln Ser Ile Gly Thr Ser Ile His 
1               5                   10      


<210>  23
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-ceramide antibody light chain variable region CDR2

<400>  23

Tyr Ala Ser Glu Ser Ile Ser 
1               5           


<210>  24
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-ceramide antibody light chain variable region CDR3

<400>  24

Gln Gln Ser Asn Ser Trp Pro Phe Thr 
1               5                   


<210>  25
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-ceramide antibody heavy chain variable region CDR1

<400>  25

Gly Tyr Thr Phe Thr Asn Tyr Trp Met His 
1               5                   10  


<210>  26
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-ceramide antibody heavy chain variable region CDR2

<400>  26

Ala Ile Tyr Pro Gly Asp Ser Asp Thr Ser Tyr Asn Gln Lys Phe Lys 
1               5                   10                  15      


Gly 
    


<210>  27
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-ceramide antibody heavy chain variable region CDR3

<400>  27

Gly Leu Tyr Tyr Gly Tyr Asp 
1               5           


<210>  28
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-ceramide antibody light chain variable region CDR1

<400>  28

Lys Ser Ser Gln Ser Leu Ile Asp Ser Asp Gly Lys Thr Phe Leu Asn 
1               5                   10                  15      


<210>  29
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-ceramide antibody light chain variable region CDR2

<400>  29

Leu Val Ser Lys Leu Asp Ser 
1               5           


<210>  30
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-ceramide antibody light chain variable region CDR3

<400>  30

Trp Gln Gly Thr His Phe Pro Tyr Thr 
1               5                   


